Dopamine agonist treatment in early Parkinson’s disease

  • U. K. Rinne
Part of the Key Topics in Brain Research book series (KEYTOPICS)


Due to insufficient antiparkinsonian efficacy, dopamine agonists alone do not seem to be useful as the primary treatment for the majority of parkinsonian patients, despite the fact that they produce only few fluctuations in disability. Early combination of dopamine agonist and a low dose of levodopa seems not only to improve parkinsonian disability, but also to inhibit the development of fluctuations in disability, especially end-of-dose disturbances and dyskinesias. Thus it appears advisable that the management of parkinsonian patients should begin in the early phase of the disease with this kind of combination.


Dopamine Receptor Dopamine Agonist Dopamine Neuron Striatal Dopamine Parkinsonian Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Birkmayer W (1976) Medical treatment of Parkinson’s disease: General review, past and present. In: Birkmayer W, Hornykiewicz O (eds) Advances in parkinsonism. Editiones Roche, Basle, pp 407–423Google Scholar
  2. Caine DB, Teychenne PF, Claveria LE, Eastman R, Greenacre JK, Petrie A (1974) Bromocriptine in parkinsonism. Br Med J 4: 442–444CrossRefGoogle Scholar
  3. Carlsson A (1983) Are “on-off” effects during chronic L-Dopa treatment due to faulty feedback control of the nigrostriatal dopamine pathway? J Neural Transm 19: 153–161Google Scholar
  4. Gessa GL (1988) Agonist and antagonist actions of lisuride on dopamine neurons: electrophysiological evidence. J Neural Transm [Suppl] 27: 201–210Google Scholar
  5. Goldstein M, Lieberman A, Meller E (1985) A possible molecular mechanism for the antiparkinsonian action of bromocriptine in combination with levodopa. Trends Pharmacol Sci 6: 436–437CrossRefGoogle Scholar
  6. Leenders KL, Herold S, Palmer AJ, Turton D, Quinn N, Jones T, Frackowiak RSJ, Marsden CD (1985) Human cerebral dopamine system measured in vivo using PET. J Cerebral Blood Flow Metab 5 /1: 157–158Google Scholar
  7. Ogawa N, Yamawaki Y, Kuroda H, Takayama H, Ota Z (1984) Differences in the effects of levodopa and bromocriptine on rat striatal dopamine receptors. Neurosciences 10: 259–266Google Scholar
  8. Poewe WH, Lees AJ, Stern GM (1986) Low-dose L-dopa therapy in Parkinson’s disease: A 6-year follow-up study. Neurology 36: 1528–1530PubMedGoogle Scholar
  9. Rajput AH, Stern W, Laverty WH (1984) Chronic low-dose levodopa therapy in Parkinson’s disease: an argument for delaying levodopa therapy. Neurology 34: 991–996PubMedGoogle Scholar
  10. Rinne UK (1981) Treatment of Parkinson’s disease: problems with a progressing disease. J Neural Transm 51: 161–174PubMedCrossRefGoogle Scholar
  11. Rinne UK (1983) New ergot derivatives in the treatment of Parkinson’s disease. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven Press, New York, pp 431–442Google Scholar
  12. Rinne UK (1985) Combined bromocriptine-levodopa therapy early in Parkinson’s disease. Neurology 35: 1196–1198PubMedGoogle Scholar
  13. Rinne UK (1986) Dopamine agonists as primary treatment in Parkinson’s disease. In: Yahr MD, Bergmann KJ (eds) Advances in neurology. Raven Press, New York, pp 519–523Google Scholar
  14. Rinne UK (1987) Early combination of bromocriptine and levodopa in the treatment of Parkinson’s disease: A 5-year follow-up. Neurology 37: 826–828PubMedGoogle Scholar
  15. Rinne UK, Sonninen V, Siirtola T (1976) Long-term treatment of parkinsonism with L-Dopa and decarboxylase inhibitor: A clinical and biochemical approach. In: Birkmayer W, Hornykiewicz O (eds) Advances in parkinsonism. Editiones Roche, Basle, pp 555–565Google Scholar
  16. Robertson GS, Robertson HA (1986) Synergistic effects of D-1 and D-2 dopamine agonists on turning behaviour in rats. Brain Res 284: 387–390CrossRefGoogle Scholar
  17. Starr BS, Starr MS (1987) Behavioural interactions involving D1 and D2 dopamine receptors in on-habituated mice. Neuropharmacology 26: 613–619PubMedCrossRefGoogle Scholar
  18. Waddington JL (1986) Behavioural correlates of the action of selective D-1 dopamine receptor antagonists. Impact of SCH 23390 and SKF 83566, and functionally interactive D-1: D-2 receptor system. Biochem Pharmacol 35: 3661–3667PubMedCrossRefGoogle Scholar
  19. Yahr MD (1976) Evaluation of long-term therapy in Parkinson’s disease: Mortality and therapeutic efficacy. In: Birkmayer W, Hornykiewicz O (eds) Advances in parkinsonism. Editiones Roche, Basle, pp 435–443Google Scholar

Copyright information

© Springer-Verlag/Wien 1989

Authors and Affiliations

  • U. K. Rinne
    • 1
  1. 1.Department of NeurologyUniversity of TurkuTurkuFinland

Personalised recommendations